Biosight Ltd. Revenue and Competitors
Estimated Revenue & Valuation
- Biosight Ltd.'s estimated annual revenue is currently $1.7M per year.
- Biosight Ltd.'s estimated revenue per employee is $155,000
Employee Data
- Biosight Ltd. has 11 Employees.
- Biosight Ltd. grew their employee count by -8% last year.
Biosight Ltd. Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 99 | -49% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Biosight Ltd.?
Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders. Biosight's lead product, BST-236 (aspacytarabine), is an innovative proprietary anti-metabolite which addresses unmet medical needs by enabling high-dose chemotherapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a Phase 2b for first-line treatment of acute myeloid leukemia (AML), following completion of a Phase 1/2a study which demonstrated tolerability with promising efficacy in the challenging population of AML patients unfit for standard of care chemotherapy. A Phase 2 study in relapsed/refractory AML and myelodysplastic syndrome (MDS) will be launched in 2020 under a collaboration agreement recently signed with the European cooperative group, GFM.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.3M | 15 | -29% | N/A |
#2 | $7.8M | 54 | 17% | N/A |
#3 | $17.2M | 58 | 14% | N/A |
#4 | $27M | 100 | -12% | N/A |
#5 | $3.5M | 109 | 35% | N/A |